Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
NCT ID: NCT00481390
Last Updated: 2011-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1110 participants
OBSERVATIONAL
2007-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Any HIV-1 infected patient will be eligible for this study including treatment naïve and experienced patients, as well as patients previously tested for HLA-B\*5701. Patients will be approached during a standard clinic visit, and will be consented prior to any study specific procedure. They will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B\*5701 status by local and central laboratories.
In selected sites patients may be asked to provide an additional blood sample. This sample will be used to develop and validate different methodologies for assessing HLA-B\*5701 status.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701
NCT00453440
Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients
NCT00441688
Evaluation and Monitoring of Patients With HIV Infectionn
NCT00557570
HIV Study on MEasuring the Reservoir on Cellular Level to CUre Infection
NCT04305665
Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients
NCT02093754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV-1 infected adults
HIV-1 infected adults
Cheek cells sample
Cheek cells sample
Blood sample
Blood sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cheek cells sample
Cheek cells sample
Blood sample
Blood sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient is willing and able to understand and provide written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK Clinical Disclosure
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, MD
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Helsinki, , Finland
GSK Investigational Site
Dublin, , Ireland
GSK Investigational Site
Alkmaar, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Arnhem, , Netherlands
GSK Investigational Site
Enschede, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Maastricht, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
The Hague, , Netherlands
GSK Investigational Site
Amadora, , Portugal
GSK Investigational Site
Lisbon, , Portugal
GSK Investigational Site
Bern, , Switzerland
GSK Investigational Site
La Chaux-de-Fonds, , Switzerland
GSK Investigational Site
Lausanne, , Switzerland
GSK Investigational Site
Lugano, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNA110329
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.